Effect of megestrol acetate combined with tamoxifen on serum levels of TSGF, PRL and HE4 in patients with endometrial cancer
GAO Tianming1, FU Qiang1, CONG Lili1, CUI Chenli1, LIU Qing2
1.Department of Obstetrics and Gynecology, Zhongshan Hospital Affiliated to Dalian University, Dalian 116001, China;
2. Pharmacy of Shanxi General Hospital of PAP, Taiyuan 030006, China
Objective To investigate the clinical efficacy of medroxyprogesterone acetate combined with tamoxifen in the treatment of endometrial cancer and its effect on serum levels of TSGF, PRL and HE4.Methods 105 patients with endometrial cancer admitted to the hospital from March 2016 to December 2018 were randomly divided into 2 groups. 50 cases in the control group were treated with medroxyprogesterone acetate tablets, 55 cases in the observation group were treated with medroxyprogesterone acetate tablets combined with tamoxifen citrate tablets. After 12 weeks of treatment, the recent treatment effect and adverse reactions of the two groups were observed, and the expression levels of TSGF, PRL and HE4 in the serum of the two groups before and after treatment were detected by enzyme-linked immunosorbent assay (ELISA).Results After 12 weeks of treatment, the effective rate of the control group was 42.00%, the clinical benefit rate was 68.00%; the effective rate of the observation group was 65.45%, the clinical benefit rate was 85.45%; the difference of the effective rate and the clinical benefit rate between the two groups was statistically significant (P The results showed that the expression of TSGF, PRL and HE4 in the serum of the patients in the observation group was significantly lower than that in the control group (P<0.05); the incidence of adverse reactions in the observation group was significantly lower than that in the control group (P<0.05).Conclusions Medroxyprogesterone acetate combined with tamoxifen can improve the clinical therapeutic effect of endometrial cancer and reduce the expression level of serum TSGF, PRL and HE4. Its clinical effect may be related to the expression of serum TSGF, PRL and HE4.
高天明, 付强, 丛丽莉, 崔晨丽, 柳青. 醋酸甲地孕酮联合他莫昔芬治疗子宫内膜癌的疗效及其对血清TSGF、PRL、HE4的影响[J]. 武警医学, 2020, 31(4): 313-316.
GAO Tianming, FU Qiang, CONG Lili, CUI Chenli, LIU Qing. Effect of megestrol acetate combined with tamoxifen on serum levels of TSGF, PRL and HE4 in patients with endometrial cancer. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(4): 313-316.
Adamiak-Godlewska A, Tarkowski R, Winkler I, et al. Stress urinary incontinent women, the influence of age and hormonal status on estrogen receptor alpha and beta gene expression and protein immunoexpression in paraurethral tissues[J]. J Physiol Pharmacol, 2018, 69(1):53-59.
Angioli R, Plotti F, Capriglione S, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study[J]. Tumour Biol, 2013, 34(1): 571-576.
2020, Vol. 31 
